Factors associated with listing for lung transplantation in IPF patients: An analysis of the pulmonary fibrosis foundation registry

Factors associated with listing for lung transplantation in IPF patients: An analysis of the pulmonary fibrosis foundation registry

Rationale and objectives: Lung transplantation is a potentially life-saving treatment option for patients with idiopathic pulmonary fibrosis (IPF); however, not all eligible candidates get referred and listed for transplantation. Amongst IPF patients within the Pulmonary Fibrosis Foundation Patient...

Full description

Bibliographic Details
Main Authors:	Christopher S. King, Emily White, Shambhu Aryal, Oksana A. Shlobin, Anju Singhal, A. Whitney Brown, Christopher Thomas, Vikramjit Khangoora, Alan Nyquist, Kevin R. Flaherty, Steven D. Nathan, Joshua J. Mooney
Format:	Article
Language:	English
Published:	Elsevier 2023-08-01
Series:	Heliyon
Subjects:	Pulmonary fibrosis Idiopathic pulmonary fibrosis Lung transplantation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405844023058267

Similar Items

Prevalence of pulmonary hypertension in patients with COVID‐19 related lung disease listed for lung transplantation: A UNOS registry analysis
by: Christopher Thomas, et al.
Published: (2023-04-01)

Pulmonary vascular dysfunction without pulmonary hypertension: A distinct phenotype in idiopathic pulmonary fibrosis
by: Steven D. Nathan, et al.
Published: (2024-01-01)

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry
by: Helen E. Jo, et al.
Published: (2019-05-01)

Multiple complications of advanced IPF in an individual patient presentation
by: Thomas Ledger, et al.
Published: (2023-04-01)

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
by: Andreas Guenther, et al.
Published: (2018-07-01)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
by: James Patrick Finnerty, et al.
Published: (2021-12-01)

Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
by: Helen E. Jo, et al.
Published: (2018-01-01)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
by: Ekaterina Krauss, et al.
Published: (2020-11-01)

Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry
by: Yangjin Jegal, et al.
Published: (2022-04-01)

Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis
by: Tejaswini Kulkarni, et al.
Published: (2024-03-01)

Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia
by: Maria S. Nashatyreva, et al.
Published: (2023-01-01)

Idiopathic pulmonary fibrosis: current diagnosis and treatment
by: Alexandre Franco Amaral, et al.
Published: (2023-08-01)

Evaluation of Regional Pulmonary Ventilation in Spontaneously Breathing Patients with Idiopathic Pulmonary Fibrosis (IPF) Employing Electrical Impedance Tomography (EIT): A Pilot Study from the European IPF Registry (eurIPFreg)
by: Ekaterina Krauss, et al.
Published: (2021-01-01)

Untargeted Metabolomics Reveals Alterations of Rhythmic Pulmonary Metabolism in IPF
by: Wei Sun, et al.
Published: (2023-10-01)

Senescent Cells in IPF: Locked in Repair?
by: Silke Meiners, et al.
Published: (2020-12-01)

Machine Learning and Single-Cell Analysis Identify Molecular Features of IPF-Associated Fibroblast Subtypes and Their Implications on IPF Prognosis
by: Jiwei Hou, et al.
Published: (2023-12-01)

Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry
by: Michael Kreuter, et al.
Published: (2017-07-01)

Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
by: Stefano Levra, et al.
Published: (2022-12-01)

Inhibition of LPA-LPAR1 and VEGF-VEGFR2 Signaling in IPF Treatment
by: Luo YL, et al.
Published: (2023-09-01)

Systematic Review and Metanalysis of Oncomarkers in IPF Patients and Serial Changes of Oncomarkers in a Prospective Italian Real-Life Case Series
by: Miriana d’Alessandro, et al.
Published: (2021-01-01)

IPF patients are limited by mechanical and not pulmonary-vascular factors – results of a derivation-validation cohort study
by: Benjamin D. Fox, et al.
Published: (2019-12-01)

Severe Fatigue is Highly Prevalent in Patients with IPF or Sarcoidosis
by: Ada E. M. Bloem, et al.
Published: (2020-04-01)

Exosomal circRNAs in the plasma serve as novel biomarkers for IPF diagnosis and progression prediction
by: Wenhua Gan, et al.
Published: (2024-03-01)

Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry
by: Monika Zurkova, et al.
Published: (2019-01-01)

Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study
by: Jieun Kang, et al.
Published: (2023-01-01)

Non-invasive continuous positive airway pressure in monolateral lung transplant patient with pneumonia and IPF
by: S. Aliberti, et al.
Published: (2016-01-01)

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
by: Colin H. Holtze, et al.
Published: (2020-02-01)

Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry
by: Jing Gao, et al.
Published: (2021-02-01)

The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry
by: Michael Kreuter, et al.
Published: (2019-03-01)

Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy
by: Miriana d’Alessandro, et al.
Published: (2021-02-01)

Mitochondrial Quality Control in COPD and IPF
by: Hiromichi Hara, et al.
Published: (2018-07-01)

Lung immune signatures define two groups of end-stage IPF patients
by: Tamara Cruz, et al.
Published: (2023-09-01)

Differential Genomic Profile in TERT, DSP, and FAM13A Between COPD Patients With Emphysema, IPF, and CPFE Syndrome
by: Javier Guzmán-Vargas, et al.
Published: (2021-08-01)

3D Single-Breath Chemical Shift Imaging Hyperpolarized Xe-129 MRI of Healthy, CF, IPF, and COPD Subjects
by: Steven Guan, et al.
Published: (2022-10-01)

Idiopathic pulmonary fibrosis - a disorder of alveolar wound repair?
by: Swiss Medical Weekly
Published: (2003-07-01)

Historical eye on IPF: a cohort study redefining the mortality scenario
by: Sara Tomassetti, et al.
Published: (2023-06-01)

Sex Differences in the Incidence and Outcomes of Patients Hospitalized by Idiopathic Pulmonary Fibrosis (IPF) in Spain from 2016 to 2019
by: Belén López-Muñiz Ballesteros, et al.
Published: (2021-08-01)

Serum Progranulin Level Might Differentiate Non-IPF ILD from IPF
by: Nóra Melinda Tóth, et al.
Published: (2023-05-01)

Mortality from idiopathic pulmonary fibrosis: a temporal trend analysis in Brazil, 1979-2014
by: Eduardo Algranti, et al.

Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
by: Ross Summer, et al.
Published: (2024-01-01)